These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21899710)

  • 1. [New information about fumaric acid esters (Fumaderm): results of a workshop of experts].
    Mrowietz U; Adamczyk A; Augustin M; Boehncke WH; Bonnekoh B; Gambichler T; Hengge U; Lippert U; Ludwig RJ; Luger T; Merk HF; Norgauer J; Philipp S; Reich K; Röcken M; Rostami-Yazdi M; Schön MP; Scola N; Sticherling M; Thaci D; Viehweg A; Wallbrecht K; Wozel G; Zouboulis CC; Neureither M
    J Dtsch Dermatol Ges; 2011 Sep; 9 Suppl 4():1-13. PubMed ID: 21899710
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of psoriasis with fumaric acid esters (Fumaderm).
    Mrowietz U; Altmeyer P; Bieber T; Röcken M; Schopf RE; Sterry W
    J Dtsch Dermatol Ges; 2007 Aug; 5(8):716-7. PubMed ID: 17659047
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of therapy-resistant Alopecia areata with fumaric acid esters.
    Venten I; Hess N; Hirschmüller A; Altmeyer P; Brockmeyer N
    Eur J Med Res; 2006 Jul; 11(7):300-5. PubMed ID: 16899425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatment with fumaric acid esters in six paediatric patients with psoriasis in a psoriasis centre.
    Steinz K; Gerdes S; Domm S; Mrowietz U
    Dermatology; 2014; 229(3):199-204. PubMed ID: 25247273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fumaderm® in daily practice for psoriasis: dosing, efficacy and quality of life.
    Walker F; Adamczyk A; Kellerer C; Belge K; Brück J; Berner T; Merten K; Núnez Gómez N; Neureither M; Röcken M; Ghoreschi K;
    Br J Dermatol; 2014 Nov; 171(5):1197-205. PubMed ID: 24813676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collagenous colitis during treatment with fumaric acid esters.
    Hoffmann K; Casetti F; Venzke T; Löckermann S; Schempp CM
    J Dtsch Dermatol Ges; 2014 Dec; 12(12):1138-40. PubMed ID: 25482705
    [No Abstract]   [Full Text] [Related]  

  • 7. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.
    Naldi L; Griffiths CE
    Br J Dermatol; 2005 Apr; 152(4):597-615. PubMed ID: 15840088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nephrotoxic action of fumaric acid].
    Mrowietz U
    Hautarzt; 2000 Aug; 51(8):615. PubMed ID: 10997319
    [No Abstract]   [Full Text] [Related]  

  • 10. Antipsoriatic effect of fumaric acid derivates.
    Skaria AM; Schmid U
    J Am Acad Dermatol; 1996 Feb; 34(2 Pt 1):323-4. PubMed ID: 8642109
    [No Abstract]   [Full Text] [Related]  

  • 11. Addition of pentoxifylline could reduce the side effects of fumaric acid esters in the treatment of psoriasis.
    Friedrich M; Sterry W; Klein A; Rückert R; Döcke WD; Asadullah K
    Acta Derm Venereol; 2001; 81(6):429-30. PubMed ID: 11859949
    [No Abstract]   [Full Text] [Related]  

  • 12. Retinoid therapy for psoriasis.
    Yamauchi PS; Rizk D; Lowe NJ
    Dermatol Clin; 2004 Oct; 22(4):467-76, x. PubMed ID: 15450342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
    Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M
    J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial.
    Langley RG; Paller AS; Hebert AA; Creamer K; Weng HH; Jahreis A; Globe D; Patel V; Orlow SJ
    J Am Acad Dermatol; 2011 Jan; 64(1):64-70. PubMed ID: 20619489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fumaric acid esters.
    Rostami Yazdi M; Mrowietz U
    Clin Dermatol; 2008; 26(5):522-6. PubMed ID: 18755371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fumaric acid esters, their place in the treatment of psoriasis.
    Ormerod AD; Mrowietz U
    Br J Dermatol; 2004 Apr; 150(4):630-2. PubMed ID: 15099356
    [No Abstract]   [Full Text] [Related]  

  • 19. Does prior treatment with fumaric acid esters predispose to tuberculosis in patients on etanercept?
    Ahmad K; McDonnell TJ; Rogers S
    Clin Exp Dermatol; 2007 May; 32(3):329. PubMed ID: 17397361
    [No Abstract]   [Full Text] [Related]  

  • 20. [Vitamin D3 analogs, oral fumaric acid, TNF-alpha antibodies. New hope for patients with psoriasis].
    Jäckle R
    MMW Fortschr Med; 2001 Oct; 143(41):4-8. PubMed ID: 11721660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.